Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Racura Oncology has invited investors to an in-person R&D symposium in Sydney on 24 March 2026, where executives and external experts will outline the science behind (E,E)-bisantrene, review clinical programs, and discuss the company’s commercialisation strategy. By showcasing its differentiated mechanism of action, late-stage development plans, and intellectual property position, the company aims to deepen investor understanding and support for its lead asset RC220 and broader partnering ambitions in global oncology markets.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology is an ASX-listed, Phase 3-stage clinical biopharmaceutical company focused on cancer therapeutics. Its lead asset, (E,E)-bisantrene, is a small-molecule anticancer agent targeting G4-DNA and RNA to inhibit the MYC oncogene, supported by new composition-of-matter patents and programs in acute myeloid leukaemia, EGFR-mutant lung cancer, and solid tumours.
Average Trading Volume: 171,877
Technical Sentiment Signal: Buy
Current Market Cap: A$437.9M
See more data about RAC stock on TipRanks’ Stock Analysis page.